

From: [Michael DeLong](#)
To: [Mucchetti, Peter](#)
Cc: [David Balto](#); [andre barlow](#)
Subject: Comments on Behalf of Consumer Groups on CVS and Aetna Merger
Date: Monday, December 17, 2018 6:00:58 PM
Attachments: [CVS-Aetna Tunney Act Consumer Group Comments 12.17.18.pdf](#)

Mr. Mucchetti,

Attached are the comments we are submitting on behalf of Consumer Reports, U.S. PIRG, Consumer Action, and the Universal Health Care Foundation of Connecticut on the merger of CVS and Aetna, arguing that the merger is harmful to competition and consumers, and urging the Court to carefully review the proposed final judgment.

The main points of the comments are:

- The Department of Justice has simply required a divestiture of Aetna's standalone individual Medicare Part D prescription drug plans in order to approve this anticompetitive merger, and its final judgment is insufficient to protect competition and consumers.
- Divestitures rarely solve the problem of anticompetitive mergers. Just two years ago, a district court held that Molina's acquisition of divested assets related to Aetna's acquisition of Humana was not enough to restore competition, and a similar remedy failed in the case of Humana and Arcadian. Aetna is divesting its Medicare Part D plans to WellCare.
- Competition between CVS and Aetna has led to lower premiums and out-of-pocket expenses, plus enhanced benefits, better drug formularies, and innovative products. WellCare is unlikely to maintain this competition.
- The CVS-Aetna merger raises significant vertical antitrust concerns. The PBM market is highly concentrated and uncompetitive, as is the health insurance market, and past vertical healthcare mergers have harmed consumers.
- Past insurer-PBM alliances have not led to lower health care prices or improved quality of care. CVS's history suggests it will use its acquisition of Aetna to stifle competition, leading to higher prescription drug prices, lower quality of care, and less consumer choice.
- The Court should carefully review the final judgment to determine if it is in the public interest and that it preserves competition. Currently the final judgment is neither of those things, and it does not resolve the major harm resulting from the merger.

Please let us know if you have any questions, and let us know that you received this email and these comments.

Sincerely,

Michael DeLong
925-708-1135
Law Offices of David Balto



December 17, 2018

Peter Mucchetti
Chief, Healthcare and Consumer Products Section
Antitrust Division
Department of Justice
450 Fifth Street NW, Suite 4100
Washington, DC 20530

Re: Comments from Consumer Reports, U.S. PIRG, Consumer Action, and Universal Health Care Foundation of Connecticut Concerning the Proposed Final Judgment in *United States v. CVS Health Corporation and Aetna, Inc.*, No. 1:18-cv-02340 (RJL)

Dear Mr. Mucchetti,

The undersigned stakeholders representing consumer organizations are concerned about the high cost of prescription drugs, escalating healthcare costs, and lack of meaningful patient choice. Pursuant to Section 2(b) of the Antitrust Procedures and Penalties Act (the “Tunney Act”), 15 U.S.C. § 16(b), we respectfully submit the following comments on the proposed Final Judgment (“PFJ”) in the captioned matter. These comments are being submitted to assist the U.S. Department of Justice (“DOJ”) and the district court in the review of whether the PFJ is sufficiently complete to remedy the competitive problems identified in the DOJ’s complaint as well as the wide range of other anticompetitive problems presented by the merger of CVS Health Corporation (“CVS”) and Aetna Inc. (“Aetna”).

I. Introduction

We acknowledge this Court’s statement in *SBC Communications* that a court “cannot look beyond the complaint in making the public interest determination unless the complaint is drafted so narrowly as to make a mockery of judicial power.” *United States v. SBC Commc’ns, Inc.*, 489 F. Supp. 2d 1, 15 (D.D.C. 2007). As explained below, the DOJ’s complaint, PFJ, and Competitive Impact Statement completely disregard serious competitive problems. But even focusing only on the four corners of the complaint, DOJ’s proposed remedy falls far short of what is required to address the problem identified in the complaint consistent with the public interest.

Here, the DOJ is merely requiring a divestiture of Aetna's standalone individual Medicare Part D prescription drug plans ("individual PDPs") to WellCare Health Plans, Inc. ("WellCare") in an effort to resolve competition concerns related to a horizontal overlap posed by the merger.

There are numerous concerns and questions about whether the divestiture package in the PFJ is adequate and whether WellCare is an appropriate buyer:

- WellCare is substantially smaller than Aetna and lacks its economies of scope and scale, brand reputation and number of covered lives;¹
- WellCare likely does not have the capacity to handle such a large increase in covered lives (growing from about 1 million to 3 million covered lives);
- The divestiture includes only contracts with subscribers and the use of the Aetna name for one year. These assets are fragile and CVS/Aetna will be in a prime position to steal back business soon after its obligations under the decree are completed;
- Even WellCare's CEO Kenneth Burdick recognizes that keeping the membership it is acquiring from Aetna is a risk;²
- WellCare is acquiring the assets at a price significantly below their supposed value (approximately \$45 per covered life);
- WellCare has failed as a divestiture buyer in the past. WellCare was a divestiture buyer of 4,000 Medicare Advantage lives in two counties in Arizona when the DOJ approved Humana's acquisition of Arcadian in 2012. Unfortunately, within two years, WellCare exited the market; and
- Finally, approval of this merger of over 2 million lives is inconsistent with Judge Bates' decision in the Aetna/Humana merger to reject a smaller divestiture of 290,000 lives.³

¹ WellCare is much smaller than Aetna; as of December 31st, 2017 Aetna's total membership was 22.2 million and it had assets of \$55.137 billion, and WellCare had 4,371 million members and assets of \$8.364 billion. And WellCare's membership of individual PDPs has declined; from 1,392,000 in 2014 to 1,152,000 in 2017. Aetna Reports Fourth-Quarter and Full Year 2017 Results, January 30, 2018. See <https://news.aetna.com/newsreleases/aetna-reports-fourth-quarter-and-full-year-2017-results/> and WellCare Health Plans, Inc. 2017 Annual Report (Form 10-K). U.S. Securities and Exchange Commission. February 2018. <https://www.sec.gov/Archives/edgar/data/1279363/000127936318000011/wcg-2017123110k.htm>

² Kenneth Burdick, WellCare CEO, October 30, 2018, WellCare Earnings Call. "Therefore, we'll be working in 2019 to enhance our products and capabilities and filing bids in June of 2019 to preserve as much membership as possible with the new WellCare products in 2020."

³ *United States v. Aetna, Inc.*, Memorandum and Opinion Filed January 23, 2017 at p. 16 and 93.

The DOJ's Complaint does not identify any other horizontal or vertical foreclosure concerns. In numerous respects, the PFJ is insufficient to protect consumers and patients.

II. Merger Remedies Increasingly Fail to Restore Competition

The PFJ is unlikely to resolve the competitive concerns raised in the DOJ's Complaint. Merger remedies including both structural and behavioral components are increasingly criticized for failing to effectively restore competition.⁴ The current administration has indicated that it has a strong preference for structural remedies over behavioral ones.⁵ The rationale for this position is that behavioral remedies inherently require the merged company to act against its incentives, and therefore, even an attempt to enforce them requires continuous regulatory monitoring that the DOJ as a law enforcement agency, is not set up for. While there is some merit in this position, the solution is not to allow a problematic merger to go forward with only inadequate divestiture remedies. A problematic merger that cannot be fully fixed with divestitures should be challenged outright. And in some cases, there may be vertical foreclosure concerns where behavioral remedies can be effective and are worth the DOJ's investment and resources and ongoing commitment. But, the alternative is never to accept an inadequate divestiture remedy. In some cases, as is here, the DOJ should simply challenge the merger.

Moreover, even structural remedies such as divestitures are inherently risky and inadequate. While the DOJ does its best to construct effective divestiture remedies, the government can never be certain how the divestiture buyer will perform with the divested assets in the future. Not surprisingly, the existing, albeit limited empirical evidence suggests that structural remedies have often failed to prevent harm to competition.⁶ Indeed, divestiture remedies have repeatedly failed to protect consumers, because in many cases no set of divestiture assets are sufficient to replace the lost competition.

Consumers are facing fewer choices and paying higher prices in a number of industries because of failed merger remedies in the airline,⁷ grocery store,⁸ dollar store,⁹ and rental car industries.¹⁰

⁴ John Kwoka, *Mergers, Merger Control, and Remedies: A Retrospective Analysis of U.S. Policy* (MIT Press 2015).

⁵ Keynote Address by Assistant Attorney General Makan Delrahim at American Bar Association's Antitrust Fall Forum, November 16, 2017. <https://www.justice.gov/opa/speech/assistant-attorney-general-makan-delrahim-delivers-keynote-address-american-bar>

⁶ Kwoka, note 1.

⁷ Catherine A. Peterman, *The Future of Airline Mergers after the US Airways and American Airlines Merger*, 79 J. Air L. & Com. 781 (2014), <https://scholar.smu.edu/jalc/vol79/iss4/3>

⁸ In 2015, the FTC approved Safeway's acquisition of Albertson's, a large grocery merger, on the condition that the merged company divest itself of 146 stores to Haggens, a small chain of 18 stores. Within months, that small chain filed for bankruptcy and the merged company wound up buying back about 36 stores. Ana Marum, *Failed divestiture: Albertsons is bidding on 36 Haggens stores, including some it used to own*, *The Oregonian*, November 10, 2015. https://www.oregonlive.com/window-shop/index.ssf/2015/11/albertsons_bids_on_36_haggens_s.html

⁹ In 2015, the FTC conditioned Dollar Tree's acquisition of Family Dollar, a merger of dollar stores, on a divestiture of stores to Sycamore, a private equity firm. The private equity buyer sold the assets to the other large national dollar store player, Dollar General, within 21 months. FTC Press Release, *"FTC Approves Sycamore Partners II, L.P. Application to Sell 323 Family Dollar Stores to Dollar General"*, April 27, 2017. <https://www.ftc.gov/news-events/press-releases/2017/04/ftc-approves-sycamore-partners-ii-lp-application-sell-323-family>

¹⁰ In 2012, the FTC conditioned Hertz's acquisition of Dollar Thrifty on a divestiture of Advantage and other assets to a small rental car company, FSNA, backed by a private equity fund and Advantage buyer filed for bankruptcy within a year only to have some of the assets auctioned back to Hertz. Bret Kendall, *How the FTC's Hertz Antitrust Fix Went Flat*, *Wall Street Journal*, December 8, 2013. <https://www.wsj.com/articles/how-the-ftc8217s-hertz-antitrust-fix-went-flat-1386547951?ns=prod/accounts-wsj>

Some of these failures were monumental, predictable, and unbelievably fast. And for health insurance it is the same story. For example, in 2012, the DOJ conditioned Humana's acquisition of Arcadian on divestitures of Medicare Advantage plans in 51 counties. Within a couple of years, WellCare and Cigna, two of three purchasers of divested assets, exited many of the markets where they had purchased the divested assets so they failed to restore competition.¹¹ While Humana shareholders benefitted, consumers and patients did not. Meanwhile, just two years ago, a district court held that Molina Healthcare's ("Molina") acquisition of divested assets related to Aetna's merger with Humana was insufficient to restore competition in Medicare Advantage markets.

A. Humana/Arcadian Failed Divestiture Remedy Suggests that DOJ's PFJ Is Unlikely to Restore Competition

The DOJ's divestiture remedy in Humana/Arcadian failed to restore competition in Medicare Advantage markets.¹² This failure suggests that it is difficult to restore or maintain competition with divestitures in the health insurance industry. First, the Humana/Arcadian remedy package included a divestiture of only 12,700 lives in 51 rural counties.¹³ If a divestiture of only 12,700 lives can fail, how can the DOJ hope to guarantee a successful divestiture of over 2.2 million lives? Second, WellCare, which was one of the divestiture buyers in Humana/Arcadian, exited the business within two years of making the acquisition.¹⁴ WellCare purchased Arcadian's Medicare Advantage business, which covered about 4,000 members in two counties in Arizona at the beginning of 2013.¹⁵ By all accounts, the DOJ believed WellCare to be a strong buyer because it was already offering Medicare Advantage plans in 12 states. But, WellCare's membership in both counties quickly declined and WellCare exited both counties by January 2015.¹⁶ In turn, Humana's Medicare Advantage membership increased in the two counties by about 35 percent, while the number of Medicare Advantage plan choices for consumers decreased.¹⁷ WellCare's history with the DOJ as a divestiture buyer indicates that it will make the best economic decision for its executives and shareholders and will not necessarily step up to the task of restoring competition.

Third, it is important to understand that the DOJ's remedy in Humana/Arcadian, like here, only called for the divestiture of contracts with subscribers. Once the next open season starts, there is no reason why the merged firm cannot just steal those subscribers back. This is exactly what happened as Humana benefitted from Cigna's and WellCare's exits. Significantly, health insurer relationships with subscribers are fragile assets on which to base a merger remedy.

And fourth, it is difficult to find divestiture buyers that have the scope and expertise to meet the obligation under the law to fully restore competition. Given WellCare's checkered past, it is not all clear that the company can meet this threshold. Moreover, the fact that Cigna, one of the

¹¹ Topher Spiro, Maura Calsyn, and Meghan O'Toole, *Divestitures Will Not Maintain Competition in Medicare Advantage*, Center for American Progress, March 8, 2016 (Center for American Progress Humana/Arcadian Analysis).

¹² Center for American Progress Humana/Arcadian Analysis.

¹³ *Justice Department Requires Divestitures in Humana Inc.'s Acquisition of Arcadian Management Services Inc.* DOJ Press Release, March 27, 2012.

¹⁴ Center for American Progress Humana/Arcadian Analysis.

¹⁵ Center for American Progress Humana/Arcadian Analysis at 3.

¹⁶ *Id.*

¹⁷ *Id.*

nation's most powerful health insurers was one of the failed buyers demonstrates how difficult it is for the DOJ to design a successful divestiture remedy in health insurance markets.

B. District Court Held That Aetna's Divestiture to Molina Was Insufficient to Preserve Competition

The DOJ's divestiture to WellCare is inconsistent with Judge Bates' decision regarding the proposed divestiture in Aetna/Humana where he was concerned that the divestiture buyer would not be able to effectively compete with the assets that it was acquiring, the low purchase price, and the divestiture buyer's lack of a success in the relevant market.

In 2016, the DOJ sued to block Aetna's acquisition of Humana alleging in part that the transaction would substantially lessen competition in Medicare Advantage markets in 364 counties. To resolve the concerns, the parties' proposed divestitures of Medicare Advantage plans to Molina, but the DOJ believed that the proposed divestiture was unlikely to effectively preserve competition. Aetna and Humana each entered into an Asset Purchase Agreement ("APA") and Administrative Services Agreement ("ASA") with Molina in an attempt to resolve competition concerns in numerous Medicare Advantage markets throughout the country.¹⁸

Under the agreements, the defendants were to transfer to Molina certain Medicare Advantage plans that included approximately 290,000 members in as many as 437 counties in 21 states.¹⁹ The proposed divestiture covered all of the areas identified as competitive concerns in the DOJ's complaint to block Aetna's acquisition of Humana. Under the ASA, Aetna and Humana were to continue to operate the divested plans for the remainder of the calendar year in which the merger closed. If it closed in 2017, then Molina would have the option to extend the ASA for up to two 6 month periods.²⁰ During that time, all plan administration services, such as IT, claims processing, and broker services, were to be managed by Aetna and Humana.²¹ Their contracts with providers would still be in place, and subscribers were to continue to see their own providers so there was a promise of no disruption to patients.²²

Though the proposed divestiture purportedly resolved all of the antitrust concerns related to the Medicare Advantage markets, Judge Bates held that the divestiture was insufficient to preserve competition. He was concerned that Molina was not an adequate divestiture buyer. Judge Bates made that decision based on a number of factors. First, contemporaneously prepared business documents from Molina's board and executives undermined the argument that the divestiture assets would enable Molina to successfully compete.²³ Second, Judge Bates was very concerned that the low purchase price that Molina paid for the Medicare Advantage contracts raised concerns about whether Molina could be a successful competitor and preserve competition in all of the problem markets.²⁴ He was concerned that because Molina was getting such a great deal it could make money and be profitable even if it abandoned many of the plans, counties, and

¹⁸ *United States v. Aetna, Inc.*, Memorandum and Opinion Filed January 23, 2017 at p. 16 and 93.

¹⁹ *Id.* at 93.

²⁰ *Id.* at 93.

²¹ *Id.* at 94.

²² *Id.* at 94.

²³ *Id.* at 105-106.

²⁴ *Id.* at 110-111.

members that it was to acquire.²⁵ Indeed, some evidence from Molina suggested that it might actually withdraw from some counties that didn't make economic sense for its business. Third, Judge Bates was concerned about Molina's history demonstrating that it had been unsuccessful in attempting to enter Medicare Advantage.²⁶ In summary, Judge Bates concluded that all these circumstances indicated that Molina was an inappropriate divestiture buyer.

Given Judge Bates rejection of the settlement proposal in Aetna/Humana, the DOJ and the district court should have similar concerns regarding WellCare's suitability in the immediate matter. The divestiture of approximately 2.2 million lives to WellCare is much larger than the 290,000 lives that were being sold to Molina so the WellCare divestiture entails greater risk. In many respects, WellCare is in a weaker position than Molina was. Therefore, the district court and the DOJ should reject the current divestiture as not in the public interest.

C. PFJ Is Unlikely To Preserve Competition In the Medicare PDP Market

The DOJ explains that "[C]ompetition between [CVS and Aetna's PDPs] has led not only to lower premiums and out-of-pocket expenses but also improved drug formularies, more attractive pharmacy networks, enhanced benefits, and innovative product features."²⁷ Here, the PFJ is unlikely to effectively preserve competition in the Medicare individual PDP markets for a number of reasons. Indeed, part of Aetna's PDP success and its ability to intensively compete with CVS relates to Aetna's status as one of the nation's largest health insurers. While the DOJ requires the complete divestiture of Aetna's Medicare PDP contracts, and allows WellCare to attempt to hire Aetna's employees, WellCare is not purchasing an existing business entity nor is it guaranteed of hiring Aetna's best employees. Under the PFJ, WellCare has a very small window of time to attempt to hire Aetna employees. This is the problem with a divestiture of assets that is not a standalone business. There is a lot of uncertainty regarding whether WellCare will be able to hire the correct personnel to help it be successful.

Moreover, there is a significant difference between Aetna and WellCare, in that WellCare does not have the same economies of scale as one of the Big 5. WellCare is much smaller than Aetna. As of December 31, 2017, Aetna's total membership of health insureds was 22.2 million and it had assets of \$55.137 billion.²⁸ WellCare had 4.371 million health insured members and assets of \$8.364 billion.²⁹ WellCare is not even in the same ball park. In 2006, WellCare had greater Medicare Part D membership of approximately 903,000 members than both CVS (approximately 400,000) and Aetna (approximately 239,000 members), but the latest enrollment numbers from Kaiser's 2018 Report, indicate that CVS has approximately 4.8 million members and Aetna has over 2.2 million members, while WellCare is now around 1 million members.³⁰ Moreover, WellCare does not appear to be a competitor that is trending in the right direction. WellCare's

²⁵ *Id.* at 110-111.

²⁶ *Id.* at 111-112.

²⁷ Competitive Impact Statement at 5.

²⁸ Aetna Reports Fourth-Quarter and Full Year 2017 Results, January 30, 2018. <https://news.aetna.com/news-releases/aetna-reports-fourth-quarter-and-full-year-2017-results/>

²⁹ WellCare Health Plans, Inc. 2017 Annual Report (Form 10-K). U.S. Securities and Exchange Commission, February 2018. <https://www.sec.gov/Archives/edgar/data/1279363/000127936318000011/wcg-2017123110k.htm>

³⁰ Medicare Part D in 2016 and Trends Over Time. Kaiser Family Foundation. September 2016, Pg. 9. <http://files.kff.org/attachment/Report-Medicare-Part-D-in-2016-and-Trends-over-Time>; Medicare Part D in 2018 and Trends Over Time. Kaiser Family Foundation. May 17, 2018.

membership of individual PDPs has actually declined over the past four years from 1,392,000 in 2014 to 1,152,000 in 2017, and this year according to the Kaiser Report, its members are around 1 million.³¹ All of this suggests that because of CVS' and Aetna's larger infrastructure that they were able to grow their Medicare Part D business much faster than WellCare.

As noted in the DOJ's Merger Remedies Guide, in some cases, the purchase of an existing business entity might be more likely to effectively preserve the competition that would have been lost through the merger.³² An existing business entity would have the "personnel, customer lists, information systems, intangible assets, and management infrastructure" necessary to compete.³³ A divestiture of an existing business is generally preferred by the DOJ and is more successful than a divestiture of some lesser set of assets because an existing business has already proved that it can compete within the marketplace.³⁴ Indeed, the DOJ's Merger Remedies Guide states that in some cases, the DOJ may require more than a divestiture of an existing business to effectively preserve competition.³⁵

Because here the DOJ is stopping short of requiring divestiture of an existing business, it requires CVS and Aetna to provide additional assistance to WellCare. The Court should be skeptical of a divestiture that relies on a continuing relationship between CVS/Aetna and WellCare because that leaves WellCare susceptible to CVS's conduct and actions which will not align with ensuring that WellCare will be an effective competitor in the future. Administrative services contracts or assistance with the transition from Aetna to WellCare simply raises a host of questions.

Under the PFJ, CVS and Aetna are required to divest to WellCare Aetna's individual PDP contracts, which includes approximately 2.2 million members in as many as 50 states. It does not impact Aetna's group or individual Medicare Advantage plans so Aetna will still be selling those products to seniors under the Aetna brand. The parties did not announce the financial terms of the deal publicly but the DOJ told the Court that the sale of the assets was for a "mere 50 to 100 million", which seems to be a very cheap price.³⁶ In fact, at most, WellCare is paying \$45 per covered life. This information is important because the DOJ and the district court should be extremely cautious about divestiture buyers that are getting a great deal.³⁷ The better a deal that a divestiture buyer has, the less incentive there is to continue to manage underperforming contracts. A low purchase price raises serious concerns as to whether WellCare will manage the assets in a way that preserves competition going forward. The Merger Remedies Guide acknowledges this possibility.³⁸ An extremely low purchase price shows the conflicting interest between the divestiture buyer and the DOJ's goal of restoring competition. If the divestiture buyer does not have much skin in the game, the inexpensive acquisition could still "produce

³¹ WellCare Annual Report.

³² DOJ Antitrust Division Policy Guide to Merger Remedies, June 2011, at 8-10. ("Merger Remedies Guide").

³³ Merger Remedies Guide, at 9.

³⁴ Merger Remedies Guide, at 8-9.

³⁵ Merger Remedies Guide, at 10.

³⁶ *United States v. CVS Health Corporation*, CV No. 18-2340 (Transcript of December 3, 2018 Motions Hearing).

³⁷ Merger Remedies Guide at 9.

³⁸ Merger Remedies Guide at 9.

something of value to the purchaser” even if it does not become a significant competitor in all aspects of the divestiture and therefore, the divestiture would not restore competition.”³⁹

Here, per the terms of the agreements, Aetna will, at the option of WellCare, provide administrative services to, and assume the financial risk of, the Aetna Part D plans through the end of plan year 2019.⁴⁰ Again, this seems like a deal that is too good to be true. The PFJ indicates that Aetna, at WellCare’s option, will provide plan administration services, such as pharmacy network management and contracting; prescription drug claims processing; utilization review and quality management; data collection, reporting and submission; rebate management; formulary administration; as well as billing and invoicing. This raises more questions because it means WellCare will be relying on the merged firm for support. This suggests that the divestiture in the PFJ is unlikely to be truly effective in restoring competition lost by the merger.

In addition, past failed remedies demonstrate that when a divestiture buyer such as WellCare acquires more than it can handle, the divestiture buyer has had trouble managing the increased growth. Here, WellCare will be tripling its size in the Medicare PDP business from 1.1 million lives to approximately 3.3 million lives. This type of rapid growth has resulted in small divestiture buyers going out of business within months of acquiring divested assets, with the result that competition and consumers lose out.⁴¹

The DOJ makes clear in its Competitive Impact Statement that neither entry nor expansion is likely to solve the competitive problems created by the merger.⁴² It notes that recent entrants into individual PDP markets have been largely unsuccessful, with many subsequently exiting the market or shrinking their geographic footprint.⁴³ The DOJ states that effective entry into the sale of individual PDPs requires years of planning, millions of dollars, access to qualified personnel, and competitive contracts with retail pharmacies and pharmaceutical manufacturers.⁴⁴ The DOJ also explains that companies attempting to enter the individual PDP market must quickly establish sufficient scale to keep their plans’ costs down.⁴⁵ This raises a lot of questions regarding whether WellCare is up to the task.

Under the PFJ, CVS and Aetna are required to provide WellCare with the Aetna brands for the Medicare PDPs for one year. The merged firm, however, will continue to use the Aetna brand for its other products. This type of “brand splitting” -- allowing the merged firm to retain access to the brand -- can present a significant competitive risk, because it will make it more difficult for WellCare to differentiate its products from Aetna’s going forward.⁴⁶ One year is a short time frame, but after two years, Aetna will be free to compete using its brand in the future. This essentially means that WellCare could end up never being as competitive, because it will not have the incentive to market its Medicare PDPs using the Aetna brand. Indeed, WellCare would never have the incentive to promote the Aetna brand because it would be in a sense advertising

³⁹ Merger Remedies Guide at 9.

⁴⁰ PFJ § IV.H; *see also* Press Release, *WellCare Completes Acquisition of Standalone Medicare Part D Prescription Drug Plan Business from Aetna*, December 4, 2018.

⁴¹ Ana Marum, *Failed divestiture: Albertsons is bidding on 36 Haggen stores, including some it used to own*, *The Oregonian*, November 10, 2015.

⁴² Competitive Impact Statement at 6.

⁴³ *Id.*

⁴⁴ *Id.*

⁴⁵ *Id.*

⁴⁶ Merger Remedies Guide at 11-12.

Aetna's other insurance plans that compete against WellCare brands. These limitations will predictably make it more difficult to preserve competition.

In any case, the question remains whether WellCare will be able to retain many of the 2.2 million subscribers that it is acquiring through the divestiture, let alone fully restore competition as is required under the law. One thing is for sure: CVS will compete to take those subscribers away from WellCare when those obligations are over.

D. Inadequate Remedy in the PFJ Will Harm Seniors

The divestitures in the PFJ will likely also result in additional cost to consumers such as disrupted and inferior service, higher premiums, and increased uncertainty. Careful scrutiny is required with the CVS/Aetna PFJ, because it involves the most vulnerable consumers – elderly and disabled Medicare beneficiaries. There is a real danger that they will suffer the greatest harm from this inadequate divestiture requirement in the PFJ. Seniors should not be forced to bear the costs of a risky settlement -- especially when the merger will only benefit CVS and Aetna shareholders and executives.

III. DOJ's Complaint and PFJ Fail to Restore Competition in Physician and Pharmacy Markets

The CVS/Aetna transaction raises significant vertical antitrust concerns that are not even raised in the DOJ's Complaint, Competitive Impact Statement, or PFJ. The DOJ simply ignored all of the concerns raised by providers, physicians, pharmacists, and consumer groups.⁴⁷ To effectively address competitive problems and ensure that consumers are fully protected, the DOJ must be willing to craft effective remedies, in addition to divestiture of a horizontal competitive overlap -- and if necessary, to challenge the merger in its entirety.

The PFJ does not address the multitude of harms to patients that would result from this vertical consolidation of the nation's largest retail pharmacy chain, and one of the two largest PBMs, with the nation's third largest health insurer.

A. PBM Market Is Concentrated and Uncompetitive

The PBM market lacks the essential elements for a competitive market -- due to the lack of choice, numerous conflicts of interest, and lack of transparency and regulation.⁴⁸ Currently, there is a lack of choice because three PBMs (CVS, Express Scripts, and UnitedHealth's OptumRx) control 85% of the PBM market.⁴⁹ The three major PBMs clearly face conflicts,

⁴⁷ E.g., Competition in the Pharmaceutical Supply Chain: The Proposed Merger of CVS Health and Aetna, House Committee on the Judiciary, February 27, 2018 (testimony of George P. Slover, Consumers Union), <https://judiciary.house.gov/wp-content/uploads/2018/02/Slover-Testimony.pdf>

⁴⁸ Testimony of David Balto, Before House Judiciary Committee, October 8, 2009.

<http://www.dcantitrustlaw.com/assets/content/documents/CAP/protecting%20consumers.pdf>

⁴⁹ Reforming Biopharmaceutical Pricing at Home and Abroad, The Council of Economic Advisors, White Paper, February 2018. The White House Council of Economic Advisors found that the three large PBMs control more than 85% of the market, "which allows them to exercise undue market power against manufacturers and against health plans and beneficiaries they are supposed to be representing, thus generating outsized profits for themselves." <https://www.whitehouse.gov/wp-content/uploads/2017/11/CEA-Rx-White-Paper-Final2.pdf>

because they own mail order operations, specialty pharmacies, and, in the case of CVS, the largest retail and specialty pharmacy chain, and the dominant long-term care pharmacy.⁵⁰ Health plans and employers contract with PBMs, which negotiate drug prices with pharmaceutical manufacturers and reimbursement rates with pharmacies.⁵¹ The PBMs control the formularies, so they determine what drugs patients are permitted to purchase, how many times patients can fill the prescription, and the amount of the patient co-pays.

A PBM such as CVS can design the benefit in such a way that patients will pay higher co-pays at rival retail pharmacies. When the PBM is commonly owned with the entity it is supposed to bargain with, or has its own mail order operations, there is an inherent conflict of interest, which can lead to deception, anticompetitive conduct, higher prices, and less choice for the patient. Because of a lack of transparency, the prescription drug rebates negotiated by PBMs from pharmaceutical manufacturers are obscured, and are not sufficiently passed on to employers or consumers and the dispensing fees reimbursed to retail pharmacies are far less than what the insurance plan is actually paying for the drug. The PBMs can make money off the spread between what they pay retail pharmacies and what they charge the insurance plan. Indeed, the PBMs are in many cases making more money per prescription than the retail pharmacy that is actually buying and dispensing the drug to patients. PBMs take advantage of a lack of transparency, misaligned incentives, and conflicts of interest to make larger profits than any other players involved in the drug supply chain (distributors, insurers, or pharmacies).⁵² In one example, CVS billed \$198.22 for a generic antipsychosis drug, but reimbursed the drug dispenser only \$5.73.⁵³ In these ways, the current structure and characteristics of the PBM market have led directly to higher drug costs.⁵⁴

B. Health Insurance Market is Concentrated

Aetna is the third largest health insurer in the United States and is considered part of the “Big 5” along with its rivals United Healthcare, Anthem, Cigna, and Humana.⁵⁵ The DOJ successfully challenged two health insurer mergers between four of the Big 5 in 2017, including Aetna.

C. Past Vertical Healthcare Mergers Have Harmed Consumers

There is little evidence that past vertical acquisitions by CVS have resulted in significant benefits to consumers. Indeed, past vertical mergers have resulted in anticompetitive conduct that has harmed independent pharmacies and consumer choice. If CVS and Aetna are allowed to join forces, the results will be predictably harmful to competition and consumers.

⁵⁰ Testimony of David Balto, Before the California Senate Committee on Business Practices and Economic Development, March 20, 2017.

<https://sbp.senate.ca.gov/sites/sbp.senate.ca.gov/files/David%20Balto%20Testimony.pdf>

⁵¹ See Robert Langreth, David Ingold, and Jackie Gu, *The Secret Drug Pricing System Middlemen Use to Rake in Millions*, Bloomberg (Sept. 11, 2018), <https://www.bloomberg.com/graphics/2018-drug-spread-pricing/>.

⁵² Charlie Grant, *Hidden Profits in the Prescription Drug Supply Chain*, Wall Street Journal, February 24, 2018, <https://www.wsj.com/articles/hidden-profits-in-the-prescription-drug-supply-chain-1519484401>

⁵³ See Robert Langreth, David Ingold, and Jackie Gu, *The Secret Drug Pricing System Middlemen Use to Rake in Millions*, Bloomberg (Sept. 11, 2018), <https://www.bloomberg.com/graphics/2018-drug-spread-pricing/>.

⁵⁴ *Id.*

⁵⁵ *United States v. Aetna Inc.*, 250 F. Supp. 3d 1, 11 (D. D.C. 2017).

In 2007, CVS acquired Caremark. After acquiring the PBM arm, CVS used its new power to exclude competition, reduce patients' access to vital healthcare services from their pharmacists of choice, and drive up prices. After closing on the acquisition, the vertically integrated firm formed exclusive pharmacy networks that prevented consumers from accessing pharmacists of their choice, and increased their costs for prescription drugs.⁵⁶ CVS will likely enter into similar exclusive arrangements if it is permitted to acquire Aetna.

In addition to the exclusive arrangements, CVS has allegedly engaged in a strategy of squeezing its rival retail pharmacies with "take-it-or-leave-it" non-negotiable contracts.⁵⁷ Rival retail pharmacies are required to sign contracts with CVS Caremark in order to process prescriptions through the PBM for payment. CVS Caremark pays dispensing fees to rival pharmacies for dispensing prescription drugs to customers, and reimburses them for the cost of prescription drugs. Because these rival pharmacies have no bargaining power, CVS was able, in the fall of 2017 and early 2018, to depress the amounts of their dispensing fees and reimbursements significantly below what they could receive in a competitive marketplace. It did so by drastically decreasing generic prescription and Medicaid reimbursement rates, while at the same time reimbursing its own CVS pharmacies at higher rates.⁵⁸ Sometimes these rival pharmacies were not reimbursed enough to even cover the cost of filling the prescription, and, in many cases, CVS was reimbursing the rival retail pharmacies less than half of what was being charged to the health insurance plans.⁵⁹ The declining reimbursement rates caused a number of rival retail pharmacies to shut their doors, reducing patients' treatment options and access.⁶⁰ To the pharmacies still in business, CVS sent letters offering to purchase them.⁶¹ Because many of the rival retail pharmacists are small and lack bargaining power, they are susceptible to exclusionary conduct and take-it-or-leave-it contracts.

Moreover, CVS has steered many of its PBM customers to its own pharmacies and mail order operation.⁶² While CVS claims that its mail order saves money for consumers and employers, there is considerable dispute regarding whether those claims are valid. Customers want choice, and even after being steered to CVS's mail order, many patients reportedly come back to their independent and community pharmacies to ask questions about their prescriptions and medications, even though they are receiving the prescription drugs from CVS's mail order. This happens because patients want access to a pharmacist who sees them regularly. These patient access concerns are particularly great in underserved inner-city and rural areas. In essence, CVS is free riding on independent and community pharmacists, and if this continues, this could eventually run these pharmacists out of business and deprive consumers of the choice they prefer.

⁵⁶ David Balto, CVS-Aetna merger is a robber baron's dream come true, *The Hill*, December 6, 2017. ("Balto Robber Baron's Dream")

⁵⁷ Linette Lopez, *What CVS is Doing to Mom and Pop Pharmacies in the U.S. Will Make You Boil*, *Business Week* (March 30, 2018). <https://www.businessinsider.com/cvs-squeezing-us-mom-and-pop-pharmacies-out-of-business-2018-3>

⁵⁸ *Id.*

⁵⁹ *Id.*

⁶⁰ *Id.*

⁶¹ *Id.*

⁶² Barbara Martinez, *CVS Appears to Steer Plan Patients to Its Stores*, *Wall St. Journal*, May 13, 2009.

While CVS proclaims that its acquisition of Aetna will result in substantial efficiencies, it is often the case that efficiencies, even if realized by the merged company, are rarely passed on to consumers in the form of lower prices and better services.

In fact, past health insurer-PBM alliances have not led to lower health care prices or improved quality of care. In 2007, UnitedHealthcare merged CatamaranRx, then the fourth-largest PBM, with its own OptumRx PBM, and in 2011, Express Scripts and Medco, two of the three largest PBMs at the time, merged. While both deals promised efficiencies that would result in lower prices for consumers, there has been no evidence of improved care, lower premiums and overall costs, increased savings, or any resulting benefits passed on to consumers.⁶³ Rather, consumers have suffered through higher drug prices, fewer choices, poorer service, and increased fraud and abuse.

D. CVS/Aetna Merger Is Likely to Harm Competition and Consumers

CVS's history suggests that it will continue to engage in exclusionary conduct to steer patients away from rivals. The acquisition of Aetna only further enhances the ability and incentive of the merged firm to impede competition in numerous respects in retail pharmacy, provider services, health insurance, and PBM services.⁶⁴

Pre-merger, Aetna has the incentive to deal with all retail pharmacies on behalf of its insureds. Post-merger, this will change as CVS/Aetna will have the increased incentive and ability to steer Aetna's insureds to CVS's mail order or its retail pharmacy stores. CVS will be able to cut off rival retail pharmacies' access to Aetna insureds, for example, by requiring the Aetna insureds to use CVS mail order and retail pharmacies or by implementing financial disincentives on to Aetna insureds that penalize them for using rival retail pharmacies.

Primary care physicians are also at risk of being squeezed out of the marketplace to the detriment of their patients.⁶⁵ CVS will be able to steer patients covered by Aetna to receive their care from CVS-run clinics, instead of from their own physicians.⁶⁶

Likewise, before the merger, a standalone CVS has strong incentives to sell its PBM services to all health insurers.⁶⁷ After integrating with Aetna, the incentive to sell such services to other health insurers changes.⁶⁸ Given the significance of being one of the three largest PBMs, CVS could implement a number of strategies related to drug formularies, providing less transparency of drug costs, and gathering information about rival insurers' drug expenditures and customers

⁶³ Balto, Robber Baron's Dream.

⁶⁴ Letter from Diana Moss, President of American Antitrust Institute to the Department of Justice, Regarding *Competitive and Consumer Concerns Raised by the CVS-Aetna Merger* dated March 26, 2018. ("AAI Letter"). Note 40, *supra*. Testimony of George P. Slover, Consumers Union.

⁶⁵ Letter from Marilyn Singleton to the Department of Justice, September 21, 2018. <http://aapsonline.org/cvs-aetna/>.

⁶⁶ *Id.*

⁶⁷ AAI Letter.

⁶⁸ *Id.*

that could be used to disadvantage health insurer rivals.⁶⁹ This could raise rival health insurers' costs for prescription drugs. Finally, CVS could cut off Aetna subscribers from rival PBMs.

In sum, patients would predictably see higher prescription drug prices, lower quality, and less choice as this merger results in CVS steering patients to its own services and products and away from competitors' offerings.

Concluding Thoughts

We urge the Court to very carefully review the PFJ. The PFJ needs to be as thorough as possible to prevent post-merger harm. We believe it falls far short of what is needed to effectively preserve competition and prevent consumer harm. The DOJ is taking a significant risk when it accepts remedies to resolve competition concerns posed by mergers and the Court must be confident that the proposed remedies are actually sufficient to prevent these harms from occurring. The remedies must ensure that healthcare markets remain competitive. History suggests that restoring competition is especially difficult in the health insurance industry. It is far from certain that any divestitures required of these merging parties will succeed today, given that they have so clearly failed in the past. Seniors are especially likely to lose out, but the harms will sweep far more broadly. The PFJ is not in the public interest because it will not preserve competition in the individual Medicare Part D PDP markets and does nothing to resolve the many harms that would predictably result from the vertical integration.

Sincerely,

Consumer Reports

U.S. PIRG

Consumer Action

Universal Health Care Foundation of Connecticut

⁶⁹*Id.*